Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
| ▸ | POLR1A | O95602 | 1/20 | 0.39 |
| ▸ | CBX7 | O95931 | 2/20 | 0.39 |
| ▸ | CDYL2 | Q8N8U2 | 2/20 | 0.39 |
| ▸ | CDYL | Q9Y232 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3507064 | 1.00 | KMT2A (0.41) | KMT2AACKR3POLR1ACBX7CDYL2 | |
| SCHEMBL3399165 | 1.00 | KMT2A (0.41) | KMT2AACKR3POLR1ACBX7CDYL2 | |
| Hydrochloric Acid SCHEMBL3403011 | 0.98 | KMT2A (0.40) | KMT2AACKR3POLR1ACBX7CDYL2 | |
| Hydrochloric Acid SCHEMBL3399186 | 0.98 | KMT2A (0.40) | KMT2AACKR3POLR1ACBX7CDYL2 | |
| SCHEMBL27788065 | 0.87 | MCHR1 (0.42) | KMT2AACKR3POLR1ACBX7CDYL2 | |
| SCHEMBL8152193 | 0.85 | KMT2A (0.41) | KMT2AACKR3POLR1ACBX7CDYL2 | |
| SCHEMBL10196415 | 0.85 | KMT2A (0.41) | KMT2AACKR3POLR1ACBX7CDYL2 | |
| SCHEMBL20606198 | 0.84 | MCHR1 (0.46) | L3MBTL3KDM1AMAOAMAOBMCHR1 | |
| SCHEMBL20896382 | 0.84 | MCHR1 (0.46) | L3MBTL3KDM1AMAOAMAOBMCHR1 | |
| SCHEMBL3431068 | 0.84 | KMT2A (0.40) | KMT2AACKR3POLR1ACBX7CDYL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250167-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | Chlorion Pharma, Inc. (CA) | 2010-11-17 | — | — | EP | disclosed |
| US-20090275538-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | UNIVERSITE LAVAL (CA) | 2009-11-05 | — | — | US | disclosed |
| WO-2009097695-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | CHLORION PHARMA, INC. (CA) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275538-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | OPRL1, OPRK1, AHR | KMT2A 1752/4885ACKR3 144/4885POLR1A 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.